Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Respiratory Failure

Clinical Trial Details

Overview

Research Study Summary

Patients are needed to participate in a clinical research study of IV Ganciclovir and Valganciclovir and Placebo to evaluate Acute Lung Injury, Acute Respiratory Distress Syndrome or Respiratory Failure

Research Study Title

A Randomized Double-Blind Placebo-Controlled Trial of Ganciclovir/Valganciclovir for Prevention of Cytomegalovirus Reactivation in Acute Injury of the Lung and Respiratory Failure (The GRAIL Study)

Purpose

To evaluate whether administration of ganciclovir reduces serum IL-6 levels (i.e. reduction between baseline and 14 days post-randomization) in immunocompetent adults with severe sepsis or trauma associated respiratory failure.

Primary Hypotheses:

  • In CMV seropositive adults with severe sepsis or trauma , pulmonary and systemic CMV reactivation amplifies and perpetuates both lung and systemic inflammation mediated through specific cytokines, and contributes to pulmonary injury and multiorgan system failure,

AND

  • Prevention of CMV reactivation with ganciclovir decreases pulmonary and systemic inflammatory cytokines that are important in the pathogenesis of sepsis and trauma related complications.
To Learn more
Phase

2

Gender

Both Male and Female

Age

18 and up

Overall Status

Recruiting

Lead Sponsor

Fred Hutchinson Cancer Research Center

Duration

47 Months

Facility Type

N/A

Eligibility

Both Male and Female ages 18 Years and up

Inclusion Criteria:

  1. Subject/next of kin informed consent

  2. Age > = 18 years

  3. CMV IgG seropositive. The following tests are acceptable:

  4. FDA licensed test in a local lab approved by the coordinating center (FHCRC, Seattle, WA).

  5. Test in central study lab (ARUP, Salt Lake City, UT)

  6. A report that patient has previously been tested and found to be CMV seropositive at any time (a credible next of kin report is acceptable; confirmatory test will be done but results are not required for randomization)

  7. Intubated and requiring mechanical positive pressure ventilation (including Acute Lung Injury/ARDS (EA Consensus Definition))

  8. Meets criteria for either:

  9. Severe sepsis criteria (as defined in appendix G) within a 24-hour time period within the 120 hour window

OR

  1. Trauma with respiratory failure and an ISS score > 15 within a 24 hour time period, and within the 120 hour window (where mechanical ventilation is not due solely to a head injury)

  2. On the day of randomization (by local criteria):

  3. Not eligible for SBT (use of sedation and/or vasopressor does not specifically contraindicate SBT),or

  4. Failed SBT

Exclusion Criteria:

  1. BMI > 60 (1st weight during hospital admission)

  2. Known or suspected immunosuppression, including:

  3. HIV+ (i.e. prior positive test or clinical signs of suspicion of HIV/AIDS; a negative HIV test is not required for enrollment)

  4. stem cell transplantation:

  5. within 6 months after autologous transplantation or

  6. within 1 years after allogeneic transplantation (regardless of immunosuppression)

  7. greater than 1 year of allogeneic transplantation if still taking systemic immunosuppression or prophylactic antibiotics (e.g. for chronic graft versus host disease)

Note: if details of stem cell transplantation are unknown, patients who do not take systemic immunosuppression and do not take anti-infective prophylaxis are acceptable for enrollment and randomization.

  • solid organ transplantation with receipt of systemic immunosuppression (any time).

  • cytotoxic anti-cancer chemotherapy within the past three months (Note: next-of-kin estimate is acceptable).

  • congenital immunodeficiency requiring antimicrobial prophylaxis (e.g. TMP-SMX, dapsone, antifungal drugs, intravenous immunoglobulin).

  • receipt of one or more of the following in the indicated time period:

  • within 6 months: alemtuzumab, antithymocyte/antilymphocyte antibodies

  • within 3 months: immunomodulator therapy (TNF-alpha antagonist, rituximab, tocilizumab, IL1 receptor antagonist and other biologics)

  • within 30 days:

  • corticosteroids > 10 mg/day (chronic administration, daily average over the time period)

  • topical steroids are permissible

  • use of hydrocortisone in "stress doses" up to 100 mg four times a day (400mg/daily) for up to 4 days prior to randomization is permissible

  • use of temporary short-term (up to 2 weeks) increased doses of systemic steroids (up tp 1 mg/kg) for exacerbation of chronic conditions are permissible.

  • methotrexate ( > 10.0 mg/week)

  • azathioprine ( > 75 mg/day)

Note: if no information on these agents is available in the history and no direct or indirect evidence exists from the history that any condition exists that requires treatment with these agents (based on the investigator's assessment), the subject may be enrolled. For all drug information, next-of-kin estimates are acceptable. See Appendix D for commonly prescribed immunosuppressive agents.

  1. Expected to survive < 72 hours (in the opinion of the investigator)

  2. Has been hospitalized for > 120 hours (subjects who are transferred from a chronic care ward, such as a rehabilitation unit, with an acute event are acceptable).

  3. Pregnant or breastfeeding (either currently or expected within one month).

Note: for women of childbearing age (18-60 years, unless documentation of surgical sterilization [hysterectomy, tubal ligation, oophorectomy]), if a pregnancy test has not been done as part of initial ICU admission work-up, it will be ordered stat and documented to be negative before randomization. Both urine and blood tests are acceptable.

  1. Absolute neutrophil count < 1,000/mm3 (if no ANC value is available, the WBC must be

2500/mm3)

  1. Use of cidofovir within seven (7) days of patient randomization. The use of the following antivirals is permitted under the following conditions:

  2. Ganciclovir, foscarnet, high-dose acyclovir, or valacyclovir until the day of randomization

  3. Acyclovir as empiric therapy for central nervous system HSV or VZV infection until the diagnosis can be excluded

  4. For enrolled patients during the active study drug phase, acyclovir, famciclovir, valacyclovir for treatment of HSV or VZV infection as clinically indicated.

  5. Currently enrolled in an interventional trial of an investigational therapeutic agent known or suspected to have anti-CMV activity, or to be associated with significant known hematologic toxicity (Note: confirm eligibility with one of the study medical directors at the coordinating site).

  6. At baseline patients who have both a tracheostomy, and have been on continuous 24-hour chronic mechanical ventilation.

  7. Patients with Child Class C Cirrhosis.

  8. Patients with pre-existing interstitial lung disease.

Site Locations (11)

Country State City Zip Facility and Contact
United States Colorado Denver 80206 University of Colorado / National Jewish Health / Swedish Medical Center
Stephen K Frankel, MD
303-398-1521
Frankels@njc.org

Marc Moss, MD
Sub-Investigator
United States Illinois Chicago 60611 Northwestern University
Richard W. Wunderink, MD
614-293-4925
r-wunderink@northwestern.edu
United States Michigan Ann Arbor 48109-5360 University of Michigan
Robert Hyzy, MD
734-936-5201
rhyzy@umich.edu

Pauline Park, MD
Sub-Investigator
United States North Carolina Winston-Salem 27157 Wakeforest University, School of Medicine
Peter Morris, MD
336-716-1210
pemorris@wakehealth.edu

Shayn Martin, MD
Sub-Investigator
United States Ohio Cleveland 44195 The Cleveland Clinic Foundation
Duncan Hite, MD
216-445-5765
guted@ccf.org
United States Ohio Columbus 43210 Ohio State University Medical Center
Matthew Exline, MD
614-293-4925
Matthew.Exline@osumc.edu

James O'Brien, MD
Sub-Investigator
United States Pennsylvania Philadelphia 19104-6160 University of Pennsylvania Medical Center
Mark Mikkelsen, MD
215-615-5416
mark.mikkelsen@uphs.upenn.edu
United States Pennsylvania Pittsburgh 15261 University of Pittsburgh Medical Center
Scott Gunn, MD
412-958-8398
gunnsr@ccm.upmc.edu

Scott Gunn, MD
Principal Investigator
United States Vermont Burlington 05405 University of Vermont College of Medicine
Polly Parsons, MD
802-847-6177
polly.parsons@vtmednet.org

Renee Stapleton, MD
Principal Investigator
United States Washington Seattle 98195 University of Washington Medical Center / Harborview Medical Center
Ajit Limaye, MD
206-598-1041
ALimaye@medicine.washington.edu

Robert Rakita, MD
Sub-Investigator

Michael Boeckh, MD
Sub-Investigator

Paul Pottinger, MD
Sub-Investigator
United States Washington Seattle 98104 Harborview Medical Center
Joseph Cuschieri, MD
206-744-6448
jcuschie@u.washington.edu

Contact

Michael Boeckh, MD
206-667-6706

NCT ID: NCT01335932

Date Last Changed: September 23, 2014

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials. Some study summaries have been edited for clarity purposes to make them easier to understand. View more study details here.